Lilly Ventures
Venture capital · Indianapolis, Indiana, United States
Portfolio collected from the firm’s website, last checked Jun 28, 2026.Raises and exits come from each company’s own SEC and company records.
8Deep-tech portfolio2 active
6Portfolio exitsAcquired or listed
0Raises, 12 monthsLatest: Olema Pharmaceuticals
12Co-investorsShare a portfolio company
Portfolio · 8 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Lyric Therapeutics | Biotech | Active | — | — |
| Versanis Bio | Biotech | Active | — | — |
| Olema Pharmaceuticals | Biotech | Public | Dec 12, 2024 | $503.5M |
| Chroma Medicine | Biotech | Acquired | Sep 1, 2023 | $135.0M |
| Prevail Therapeutics | Biotech | Acquired | Mar 14, 2018 | $57.0M |
| Evotec | Biotech | Public | — | — |
| Merus | Biotech | Acquired | — | — |
| Morphic Therapeutic | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#53
Portfolio exits#31
Raises, 12 months#88
Co-investors#150
Co-investors
- Eli LillyVenture capital3 shared
- OrbiMedVenture capital3 shared
- RA CapitalVenture capital3 shared
- Foresite CapitalVenture capital2 shared
- Biotechnology Value FundVenture capital1 shared
- F-Prime CapitalVenture capital1 shared
- IncyteVenture capital1 shared
- Lysosomal TherapeuticsVenture capital1 shared
- MedicxiVenture capital1 shared
- New Enterprise AssociatesVenture capital1 shared
Sectors
- Biotech8
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.